Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USA.
Department of Surgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USA.
J Cancer Surviv. 2021 Feb;15(1):29-39. doi: 10.1007/s11764-020-00908-5. Epub 2020 Aug 17.
Many patients with hormone receptor-positive (HR+) breast cancer do not adhere to endocrine therapy (ET), and treatment-related side effects are often discussed by participants in online breast cancer forums. Our aim was to survey this unique group of patients about their ET-related experiences.
We partnered with patients active in breast cancer social media communities to develop a survey assessing ET-related side effects and medical team communication. Patients with a history of HR+ breast cancer who had received a recommendation to take ET were eligible to participate in the anonymous, online survey.
Respondents included 2353 women and 54 men. Aromatase inhibitors were the most commonly used medication. Side effects were reported by 91.2%, were more often experienced by women than men (p < 0.001), and were primarily related to medication type. Approximately one-third of respondents discontinued therapy early. While most felt supported by their medical team, 31.5% reported that their side effects were dismissed or minimized. Survey respondents most frequently reported that a healthy diet and exercise, yoga/acupuncture, and vitamins/supplements were helpful in managing ET-related side effects.
ET-related side effects are very common, and one-third discontinued treatment early. Lifestyle changes and complementary therapies can be important tools for side effect management. One-third of patients did not feel that their side effects were taken seriously.
This is the largest survey of ET use by participants in online breast cancer communities. Further research is needed to identify strategies to improve treatment adherence and to better manage ET-related side effects.
许多激素受体阳性(HR+)乳腺癌患者不遵守内分泌治疗(ET),而与治疗相关的副作用通常是在网上乳腺癌论坛的参与者中讨论的。我们的目的是调查这一独特群体的患者的 ET 相关经历。
我们与活跃在乳腺癌社交媒体社区的患者合作,开发了一项评估 ET 相关副作用和医疗团队沟通的调查。符合以下条件的 HR+乳腺癌患者有资格参与这项匿名在线调查:已接受建议接受 ET 治疗。
共有 2353 名女性和 54 名男性受访者。芳香化酶抑制剂是最常用的药物。91.2%的患者报告有副作用,女性比男性更常报告(p<0.001),且主要与药物类型有关。大约三分之一的患者提前停止了治疗。尽管大多数患者感到得到了医疗团队的支持,但仍有 31.5%的患者表示他们的副作用被忽视或最小化。调查受访者最常报告健康饮食和锻炼、瑜伽/针灸和维生素/补品有助于管理 ET 相关副作用。
ET 相关副作用非常常见,三分之一的患者提前停止了治疗。生活方式的改变和补充疗法可能是管理副作用的重要工具。三分之一的患者表示他们的副作用没有得到重视。
这是对在线乳腺癌社区参与者中 ET 使用情况的最大规模调查。需要进一步研究,以确定提高治疗依从性和更好地管理 ET 相关副作用的策略。